Back to top

earnings-consensus: Archive

Zacks Equity Research

Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SNDXNegative Net Change

Zacks Equity Research

Wall Street Analysts Believe IREN Limited (IREN) Could Rally 25.03%: Here's is How to Trade

The mean of analysts' price targets for IREN Limited (IREN) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IRENPositive Net Change

Zacks Equity Research

How Much Upside is Left in Omnicom (OMC)? Wall Street Analysts Think 25.37%

The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in Omnicom (OMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

OMCPositive Net Change

Zacks Equity Research

Wall Street Analysts Think Carter Bankshares (CARE) Could Surge 26.44%: Read This Before Placing a Bet

The consensus price target hints at a 26.4% upside potential for Carter Bankshares (CARE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CAREPositive Net Change

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VRTXNegative Net Change REGNNegative Net Change

Zacks Equity Research

Primoris Services (PRIM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Primoris Services (PRIM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRIMNegative Net Change MTZNegative Net Change

Zacks Equity Research

Analysts Estimate SiriusPoint (SPNT) to Report a Decline in Earnings: What to Look Out for

SiriusPoint (SPNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SPNTPositive Net Change MTGPositive Net Change

Zacks Equity Research

Earnings Preview: Trex (TREX) Q2 Earnings Expected to Decline

Trex (TREX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TREXPositive Net Change

Zacks Equity Research

Palomar (PLMR) Earnings Expected to Grow: Should You Buy?

Palomar (PLMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PLMRNegative Net Change ALLNegative Net Change

Zacks Equity Research

Palantir Technologies Inc. (PLTR) Earnings Expected to Grow: Should You Buy?

Palantir Technologies (PLTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PLTRNegative Net Change RDDTPositive Net Change

Zacks Equity Research

CPI Card Group Inc. (PMTS) Earnings Expected to Grow: What to Know Ahead of Q2 Release

CPI Card Group (PMTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PMTSNegative Net Change

Zacks Equity Research

Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KRYSNegative Net Change BMYNegative Net Change

Zacks Equity Research

MVB Financial (MVBF) to Report Q2 Results: What Awaits?

MVB Financial (MVBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MVBFPositive Net Change

Zacks Equity Research

Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARDXNegative Net Change UTHRNegative Net Change

Zacks Equity Research

Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?

Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INSPPositive Net Change OMCLNegative Net Change

Zacks Equity Research

JBT Marel (JBTM) Reports Next Week: Wall Street Expects Earnings Growth

JBT (JBTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JBTMNegative Net Change MIRNegative Net Change

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Reports Next Week: Wall Street Expects Earnings Growth

Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HIMSNegative Net Change IRTCNegative Net Change

Zacks Equity Research

Analysts Estimate Helios Technologies (HLIO) to Report a Decline in Earnings: What to Look Out for

Helios Technologies (HLIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HLIONegative Net Change GTESNegative Net Change

Zacks Equity Research

Ichor Holdings (ICHR) Reports Next Week: Wall Street Expects Earnings Growth

Ichor Holdings (ICHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICHRNegative Net Change QCOMNegative Net Change

Zacks Equity Research

Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDXXNegative Net Change

Zacks Equity Research

Diamondback Energy (FANG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Diamondback (FANG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FANGPositive Net Change SMPositive Net Change

Zacks Equity Research

Freshpet (FRPT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Freshpet (FRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FRPTPositive Net Change INGRPositive Net Change

Zacks Equity Research

Hagerty, Inc. (HGTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Hagerty (HGTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HGTYNegative Net Change

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRSPNegative Net Change ILMNNegative Net Change

Zacks Equity Research

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CSTLNegative Net Change MRNANegative Net Change